Date: 2014-07-02
Type of information: Development agreement
Compound: EpiScreen™ to determine the potential immunogenicity of the antibodies provided by Synthon
Company: Antitope, an Abzena company (UK), Synthon Biopharmaceuticals (The Netherlands)
Therapeutic area: Technology - Services
Type agreement: development collaboration
Action mechanism:
Disease:
Details: * On July 2, 2014, Antitope, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals, a global pharmaceutical company with expertise in the development of complex small molecule and biosimilar drugs and new biopharmaceuticals, including antibody drug conjugates (“ADC”), to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes. Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human T cell assay to determine the potential immunogenicity of the antibodies provided by Synthon. The EpiScreen™ technology correlates with published clinical anti-drug antibody immunogenicity data which supports selection of lead product candidates with low immunogenicity during preclinical development.
Financial terms:
Latest news:
